Cerus' INTERCEPT Blood System Evaluated in DRK Blood Donation Service Study
ByAinvest
Thursday, Jan 22, 2026 7:34 am ET1min read
CERS--
The German Red Cross Blood Donation Service Baden-Württemberg – Hessen has started the INITIATE study to evaluate the use of Cerus' INTERCEPT Blood System in routine clinical practice. The study aims to assess the safety profile of pathogen-inactivated platelet concentrates and their feasibility in the German healthcare system. Cerus' vice president, Christian Boutemy, stated that the company is honored to have been chosen for this study, highlighting their shared commitment to advancing blood safety and transfusion medicine.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet